- Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
- Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
- Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
- Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
- Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
- Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
- Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
- Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
- Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
- Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
More ▼
Key statistics
On Thursday, Tiziana Life Sciences Ltd (TLSA:NAQ) closed at 0.7407, 80.66% above the 52 week low of 0.41 set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.781 |
---|---|
High | 0.82 |
Low | 0.7403 |
Bid | 0.72 |
Offer | 0.7943 |
Previous close | 0.81 |
Average volume | 132.98k |
---|---|
Shares outstanding | 103.09m |
Free float | 65.00m |
P/E (TTM) | -- |
Market cap | 83.50m USD |
EPS (TTM) | -0.1496 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼